Additionally, a significant association with tumor grade was also observed for the rs603965 polymorphism in G versus A (allele comparison, p = 0.02, OR = 0.74, 95% CI 0.59-0.95, I<sup>2</sup> = 26%).
Moreover, in stratified analyses by type of disease, we noticed that the rs603965 polymorphism was significantly associated with the susceptibility to glioma, but such positive results were not detected in pituitary adenoma or meningioma.
Moreover, in stratified analyses by type of disease, we noticed that the rs603965 polymorphism was significantly associated with the susceptibility to glioma, but such positive results were not detected in pituitary adenoma or meningioma.
Moreover, in stratified analyses by type of disease, we noticed that the rs603965 polymorphism was significantly associated with the susceptibility to glioma, but such positive results were not detected in pituitary adenoma or meningioma.
The C allele of <i>BRCA2</i>:rs15869 (OR, 1.600; <i>p</i>=0.041) and the C allele of <i>CCND1</i>:rs7177 (OR, 1.555; <i>p</i>=0.041) were associated with high tumor histologic grade.
Moreover, we observed opposite associations between the CCND1 splice site polymorphism rs9344 G870A and the frequency of CAs compared to their association with translocation t(11,14).
<b>Results:</b> Overall, the cumulative findings demonstrated that <i>CCND1</i> polymorphism (rs9344) was not significantly associated with cancer risk in all the genetic models studied (dominant model: GG vs GA+AA: OR (95%CI) = 0.81 (0.60-1.09), <i>P</i>=0.17; recessive model: GG+GA vs AA: OR (95%CI) = 1.23 (0.96-1.59), <i>P</i>=0.11; co-dominant model: <b>GG vs AA: OR (95%CI) = 1.35 (0.93-1.97), <i>P</i>=0.12;</b> co-dominant model: <b>(GG vs GA: OR (95%CI) = 1.16 (0.85-1.59), <i>P</i>=0.34</b>; allelic model: A vs G: OR (95%CI) = 1.20 (1.14-2.85), <i>P</i>=0.23; allelic model: G vs A: OR (95%CI) = 0.83 (0.62-1.12), <i>P</i>=0.23).
We investigated the <i>CCND1</i> rs9344 (G870A) polymorphism and the expression profiles of wild-type <i>CCND1a</i> and shortened oncogenic isoform <i>CCND1b</i> at the mRNA and protein levels in 286 thyroid tumors.
<b>Results:</b> Overall, the cumulative findings demonstrated that <i>CCND1</i> polymorphism (rs9344) was not significantly associated with cancer risk in all the genetic models studied (dominant model: GG vs GA+AA: OR (95%CI) = 0.81 (0.60-1.09), <i>P</i>=0.17; recessive model: GG+GA vs AA: OR (95%CI) = 1.23 (0.96-1.59), <i>P</i>=0.11; co-dominant model: <b>GG vs AA: OR (95%CI) = 1.35 (0.93-1.97), <i>P</i>=0.12;</b> co-dominant model: <b>(GG vs GA: OR (95%CI) = 1.16 (0.85-1.59), <i>P</i>=0.34</b>; allelic model: A vs G: OR (95%CI) = 1.20 (1.14-2.85), <i>P</i>=0.23; allelic model: G vs A: OR (95%CI) = 0.83 (0.62-1.12), <i>P</i>=0.23).
We found the genotype and allele frequency distribution of rs194</span>4129 and rs7177 were significantly associated with risk of RCC (<i>P</i> = 0.015 and <i>P</i> = 0.018, respectively).
We found the genotype and allele frequency distribution of rs1944129 and rs</span>7177 were significantly associated with risk of RCC (<i>P</i> = 0.015 and <i>P</i> = 0.018, respectively).
In some subgroups, cyclin D1 gene CCND1 rs9344 and inhibitor of κB kinase gene IKBKB rs12676482 were related with the grade 3-4 acute radiation-induced myelosuppression, and CCND1 rs9344 was also associated with grade 3-4 acute radiation-induced oral mucositis.
In some subgroups, cyclin D1 gene CCND1 rs9344 and inhibitor of κB kinase gene IKBKB rs12676482 were related with the grade 3-4 acute radiation-induced myelosuppression, and CCND1 rs9344 was also associated with grade 3-4 acute radiation-induced oral mucositis.
For the rs603965 polymorphism of the CCND1 gene, we observed a protection effect for the colon cancer location under the dominant model (OR=0.49, P=0.0477).
For the rs603965 polymorphism of the CCND1 gene, we observed a protection effect for the colon cancer location under the dominant model (OR=0.49, P=0.0477).
Our comprehensive meta-analysis suggests that the polymorphism rs678653 in CCND1 has no association with cancer risk in different population and disease contexts, indicating that CCND1 rs678653 does not serve a significant biological function in predicting cancer risk.
Our comprehensive meta-analysis suggests that the polymorphism rs678653 in CCND1 has no association with cancer risk in different population and disease contexts, indicating that CCND1 rs678653 does not serve a significant biological function in predicting cancer risk.
It was observed that a 6-fold increased breast cancer risk (odds ratio/OR=5.75, 95% confidence interval/CI=1.26-26.33) was associated with Cys7Tyr in breast cancer patients when compared with healthy controls.
It was observed that a 6-fold increased breast cancer risk (odds ratio/OR=5.75, 95% confidence interval/CI=1.26-26.33) was associated with Cys7Tyr in breast cancer patients when compared with healthy controls.